OXGN $2.40 Drei Krebsmedikamente in der Pipeline!

Ticker: OXGN
Preis $2.40
Webseite:http://www.oxigene.com
Cash: $8.5M
13,329,229 shares of outstanding
Charts:




 

Der MACD ist heute den ersten Tag positiv!  

2011 Best of ASCO® Miami Meeting
Friday, July 29 and Saturday, July 30, 2011
Hyatt Regency Miami

2011 Best of ASCO® Seattle Meeting
Friday, August 5 and Saturday, August 6, 2011
The Westin Seattle  

..unter 2 USD könnte man ne erste Posi aufbauen! Meine Meinung und keine Kaufempfehlung

 

Bin mal gespannt auf die Kerze im Wochenchart am Ende dieser Woche!  

OXGN hat heute einen doppelten Boden bei $2.15 geformt!
Habe heute nocheinmal meine Positionen aufgestockt.... ASCO kann kommen!  

img src="http://elite.finviz.com/....ashx?ta=1&p=d&s=l&t=OXGN">  

 

OXiGENE ( $OXGN ) reports cash of approximately $8.5 million

As of July 8, 2011, shares of common stock in an aggregate offering amount of $19,156,051 have been sold under the July 21, 2010, January 1, 2011, June 1, 2011, and June 29, 2011 prospectus supplements, and no further sales of shares will be made under such prospectus supplements. Sales of common stock under the July 8, 2011 prospectus supplement will be made from time to time as market conditions warrant, in the Company's discretion.

The Agreement has been previously filed as Exhibit 10.1 to our Current Report on
Form 8-K on July 21, 2010 and is incorporated herein by reference. A copy of
the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., relating to
the legality of the shares, is filed as Exhibit 5.1 to this Current Report and
is incorporated by reference into the registration statement.
As of June 30, 2011, OXiGENE expects to report cash, cash equivalents and restricted cash of approximately $8.5 million, compared with approximately $2.7 million at March 31, 2011.

Source:
http://www.dailyfinance.com/company/oxigene-inc/...18/pdf/sec-filings  

We are offering shares of our common stock having an aggregate offering price of up to $3,100,000 from time to time through our sales agent, McNicoll, Lewis & Vlak LLC (“MLV”). These sales, if any, will be made pursuant to the terms of an At Market Issuance Sales Agreement entered into between us and our sales agent on July 21, 2010, a copy of which was filed with the Securities and Exchange Commission as an exhibit to our Current Report on Form 8-K on July 21, 2010, and is incorporated herein by reference.
Our common stock is listed on The NASDAQ Capital Market under the symbol “OXGN.” On May 12, 2011, the last reported sale price of our common stock was $5.60 per share and on July 7, 2011, the last reported sale price of our common stock was $2.43. The market value of our outstanding common equity held by non-affiliates as of the date of this prospectus supplement was approximately $66,778,085, based on 13,329,229 shares of outstanding common stock, of which 11,924,658 shares were held by non-affiliates, and based on the closing sale price of our common stock on May 12, 2011 of $5.60. As of the date of this prospectus supplement, we have sold securities in an aggregate offering amount of $19,156,051 pursuant to General Instruction I.B.6. of Form S-3 during the 12 calendar month period that ends on, and includes, the date of this prospectus supplement.
Sales of shares of our common stock under this prospectus, if any, may be made in privately negotiated transactions and/or any other method permitted by law, including sales deemed to be an “at the market” offering as defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on The NASDAQ Capital Market, the existing trading market for our common stock, or sales made to or through a market maker other than on an exchange. The sales agent will make all sales using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreeable terms between the sales agent and us.
Unless we and our sales agent otherwise agree, we will pay our sales agent a commission fee of up to 5% of each sale of common stock to be sold pursuant to this prospectus. Any other fee arrangement or commission amount to be received by the sales agent will be disclosed in a separate prospectus supplement for such shares. The net proceeds to us that we receive from sales of our common stock will depend on the number of shares actually sold and the offering price for such shares. Based on the trading price of our common stock, our current public float and the absence of a minimum offering amount provided for under the sales agreement, we may not be able to raise the full $3,100,000 in gross proceeds contemplated by this prospectus supplement. The actual proceeds to us will vary.
In connection with the sales of common stock on our behalf, the sales agent will be deemed an “underwriter” within the meaning of the Securities Act of 1933, as amended, and the compensation of the sales agent will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to the sales agent against certain liabilities, including liabilities under the Securities Act of 1933, as amended.  

Nächste Woche könnte es bei OXGN endgültig nach oben gehen, da das letzte Aktienpaket im Wert von $3.1M am Markt platziert worden ist.
Das Unternehmen hat bereits in der ersten Juliwoche verkündet , dass es über genügend Cash verfügt und auf keine weitere Kapitalerhöhung innerhalb der nächsten Monate angewiesen ist.

Das Unternehmen verbrennt pro Monat etwa $1M.
Also kann man sagen, dass mindestens 8-10 Monate keine Verwässerung mehr stattfinden wird.
Des Weiteren steht die ASCO.
Phantasie besteht aus eventueller Partnergewinnung zur gemeinsamen Vermarktung eines Krebsmedikaments sowie eine potentielle Übernahme durch ein größeres Pharmaunternehmen....  

Heute nocheinmal bei $1.47 meine letzte Portion OXGN Aktien gekauft der Hoffnung gute Zahlen am 10. Aug. 2011 vom Unternehmen präsentiert zu bekommen!  

$OXGN - 2011 Best of ASCO® Seattle Meeting
Friday, August 5 and Saturday, August 6, 2011
The Westin Seattle  

möglich (meine Meinung)

 

aktuell über 24 Prozent Plus!!!

 

sk $1.55 +39,64%  

Price target on $OXGN at $4.21
http://hotpennystocksonline.com/?p=595  

OXiGENE Reports Second Quarter 2011 Financial Results

http://ih.advfn.com/...pid=nmona&article=48783633&symbol=OXGN  

Jederzeit für ein Verdoppelung gut! Ein paar habe ich mir heute ins Depot genommen.
Mal schauen wie sich das Ganze entwickelt....  

 

und das bei steigendem Kurs.....  

Partnership oder Buyout news sollen bald veröffentlicht werden.
Aktueller Kurs $1.33  

$OXGN termination of Kingsbridge $40M deal means OXGN gonna face a buyout or a partnership with a huge biotech company!
I am buying all I can below $1.30 !

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8189481

Termination of a Material Definitive Agreement.

On October 13, 2011, OXiGENE, Inc. (the “Company”) notified Kingsbridge Capital Limited (“Kingsbridge”) of the termination of its Committed Equity Financing Facility (“CEFF”) with Kingsbridge, pursuant to which Kingsbridge had committed to purchase, subject to certain conditions, up to $40 million of the Company’s common stock.  Effective as of October 14, 2011, the CEFF was terminated by the Company pursuant to Section 8.2(c) of the common stock purchase agreement (the “Common Stock Purchase Agreement”) with Kingsbridge, dated as of February 19, 2008, as amended.

In connection with the CEFF, on February 19, 2008, OXiGENE also issued a warrant (the “Warrant”) to Kingsbridge to purchase up to 12,500 shares of OXiGENE common stock.  The Warrant remains exercisable until August 19, 2013, subject to certain conditions.  

New letter from CEO
http://www.oxigene.com/files/Letter_from_CEO_oct132011.pdf

...On the clinical front, shortly we expect to have the final overall survival data from our completed Phase 2 study in non-small cell lung cancer (the FALCON study) which compared the standard chemotherapy treatment regimen for these patients, consisting of
carboplatin, paclitaxel and bevacizumab with and without ZYBRESTAT. We hope to be ready to talk about these results at our upcoming quarterly earnings call in November 2011....  

$AZN Partnership deal or buyout with OXGN?

Jerry McMahon Board Director @ OXiGENE, Inc.
Senior Vice President, R&D Oncology iMED Head @ MedImmune.
http://www.linkedin.com/pub/jerry-mcmahon/20/521/182

MedImmune , the global biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, rewarding careers to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.